Integral Health Asset Management LLC Sells 10,000 Shares of Elevance Health, Inc. $ELV

Integral Health Asset Management LLC decreased its stake in Elevance Health, Inc. (NYSE:ELV) by 16.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,000 shares of the company’s stock after selling 10,000 shares during the quarter. Elevance Health accounts for about 1.1% of Integral Health Asset Management LLC’s portfolio, making the stock its 23rd largest position. Integral Health Asset Management LLC’s holdings in Elevance Health were worth $16,156,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in Elevance Health in the second quarter valued at approximately $1,148,379,000. Sanders Capital LLC boosted its position in shares of Elevance Health by 24.7% during the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after purchasing an additional 1,152,440 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after buying an additional 901,626 shares during the period. First Eagle Investment Management LLC grew its holdings in shares of Elevance Health by 25.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after buying an additional 798,457 shares during the period. Finally, Beutel Goodman & Co Ltd. bought a new stake in shares of Elevance Health in the 2nd quarter valued at $293,141,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Trading Up 1.3%

Shares of NYSE:ELV opened at $291.69 on Friday. The company’s 50-day moving average price is $338.25 and its two-hundred day moving average price is $334.11. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The stock has a market capitalization of $64.38 billion, a PE ratio of 11.61, a price-to-earnings-growth ratio of 1.59 and a beta of 0.51.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is currently 27.39%.

Analysts Set New Price Targets

Several analysts recently commented on the company. Wolfe Research set a $425.00 price objective on Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Sanford C. Bernstein dropped their target price on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. UBS Group set a $400.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Finally, Truist Financial dropped their price target on Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $387.40.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.